Italia markets closed

Ultragenyx Pharmaceutical Inc. (0LIF.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
39,94-7,97 (-16,64%)
Alla chiusura: 06:12PM BST
Schermo intero
Chiusura precedente47,91
Aperto39,94
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno39,94 - 39,94
Intervallo di 52 settimane39,94 - 39,94
Volume25
Media VolumeN/D
Capitalizzazione23,263M
Beta (5 anni mensile)1,22
Rapporto PE (ttm)N/D
EPS (ttm)-6,87
Prossima data utili31 ott 2022 - 04 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

    NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that additional data from Mereo’s Phase 2b ASTEROI

  • GlobeNewswire

    Ultragenyx to Participate at Citi BioPharma Conference

    NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET. The live and archived webcast of the presentation w

  • GlobeNewswire

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approv